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Pure hereditary spastic paraplegia (SPG) type 4 is the most common form of autosomal dominant hereditary SPG,
a neurodegenerative disease characterized primarily by hyperreflexia and progressive spasticity of the lower limbs.
It is caused by mutations in the gene encoding spastin, a member of the AAA family of ATPases. We have screened
the spastin gene for mutations in 15 families consistent with linkage to the spastin gene locus, SPG4, and have
identified 11 mutations, 10 of which are novel. Five of the mutations identified are in noninvariant splice-junction
sequences. Reverse transcription–PCR analysis of mRNA from patients shows that each of these five mutations
results in aberrant splicing. One mutation was found to be “leaky,” or partially penetrant; that is, the mutant allele
produced both mutant (skipped exon) and wild-type (full-length) transcripts. This phenomenon was reproduced
in in vitro splicing experiments, with a minigene splicing-vector construct only in the context of the endogenous
splice junctions flanking the splice junctions of the skipped exon. In the absence of endogenous splice junctions,
only mutant transcript was detected. The existence of at least one leaky mutation suggests that relatively small
differences in the level of wild-type spastin expression can have significant functional consequences. This may
account, at least in part, for the wide ranges in age at onset, symptom severity, and rate of symptom progression
that have been reported to occur both among and within families with SPG linked to SPG4. In addition, these
results suggest caution in the interpretation of data solely obtained with minigene constructs to study the effects
of sequence variation on splicing. The lack of full genomic sequence context in these constructs can mask important
functional consequences of the mutation.
Introduction
The hereditary spastic paraplegias (SPGs) are a geneti-
cally heterogeneous group of neurodegenerative disor-
ders characterized by progressive lower-limb spasticity
and hyperreflexia, occurring in the absence (pure SPG)
or presence (complicated SPG) of other major clinical
abnormalities, such as optic neuropathy, deafness, and
mental retardation (Fink 1997). Neuropathologically,
SPG is characterized by axonal degeneration that is max-
imal at the distal ends of the longest axons of the CNS
(McDermott et al. 2000). The genetic heterogeneity of
SPG is reflected by the fact that, to date, 112 SPG loci
have been identified, including loci for pure and com-
plicated autosomal dominant, autosomal recessive, and
X-linked SPG.
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The most common form of autosomal dominant pure
SPG (MIM 182601) is caused by mutations in the gene
encoding spastin, a member of the AAA family of ATP-
ases (Hazan et al. 1999). The members of this family
are characterized by the presence of one or more highly
conserved AAA motifs that contain Walker-homology
domains and harbor the ATPase activity. The AAAATP-
ases are thought to act as molecular chaperones in the
assembly, function, and disassembly of protein com-
plexes and play essential roles in a wide variety of cel-
lular activities, including protein degradation, vesicle-
mediated protein transport, cell-cycle regulation,
organelle biogenesis, and gene expression (Patel and
Latterich 1998; Neuwald et al. 1999).
The 140 spastin gene mutations described to date
include missense, nonsense, and splice-site point mu-
tations, as well as insertions and deletions, and almost
all seem to affect, either directly or indirectly, the AAA
motif–encoding region of the gene (Bu¨rger et al. 2000;
Fonknechten et al. 2000; Hentati et al. 2000; Lindsey
et al. 2000; Santorelli et al. 2000). In the present study,
we screened the spastin gene for mutations in the pro-
bands of 15 families with autosomal dominant pure
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Table 1













465GrT Exon 1 Stop codon (E114X) 1890 (4) 1.1/1.47 47 [39–62]
1486insA Exon 11 Frameshift 1939 (10) 4.1/4.47 35.5 [20–45]
Missense:
1620CrT Exon 13 R499C 2182 (4) 2.2/1.92 24.5 [3–40]
1809CrG Exon 15 R562G 1380 (11) 2/3.34 24.5 [1–40]
Invariant (GT–––AG) splice-site sequence:
IVS91GrA Intron 9 Skipped exon 9 1974 (4) .9/.75 34.8 [20–50]
IVS122ArC Intron 12 Skipped exon 13 1858 (6) 1.1/1.09 37.8 [1–59]
Others that affect splicing:
995GrT Exon 5 Exon 5 skipping; K290N 1713 (10) 3.2/2.09 30.8 [18–46]
1367ArG Exon 9 4-nt deletion from 3′ end
of exon 9 (K414K)
1676 (7) 3.2/1.64 36.7 [23–43]
IVS94ArG Intron 9 Exon 9 skipping 1838 (12) 3.8/3.82 32.2 [2–56]
IVS96TrG Intron 9 Exon 9 skipping 2082 (8) 3.3/2.47 25.1 [10–36]
IVS112insT Intron 11 Exon 11 skipping 2187 (6) 1.3/1.32 30.8 [5–40]
None detected:
… … … 1806 (3) 1.9/1.23 56.5 [42–71]
… … … 1884 (4) .8/.86 22 [4–32]
… … … 1891 (5) .9/1.35 24 [18–28]
… … … 1985 (5) .9/.6 31 [20–48]
a Nucleotide numbering is that used by Genoscope Centre National de Se´quenc¸age.
SPG and investigated the effects that some of these mu-
tations have on splicing of the spastin gene transcript.
Families and Methods
Families
Informed consent, blood samples, and clinical eval-
uations were obtained from all participating family
members, under protocols approved by institutional re-
view boards. Fifteen families, some of whom have been
described elsewhere (Scott et al. 1997), were included in
the spastin gene mutation analysis; they are listed in
table 1, together with the maximum expected LOD score
and maximum LOD score calculated for each family at
SPG4-linked marker D2S352 or D2S367. The maxi-
mum expected LOD scores were calculated with SIM-
LINK (Boehnke 1986; Ploughman and Boehnke 1989),
under the assumptions of an autosomal dominant model
with age-dependent penetrance, a disease-allele fre-
quency of .001, and a marker with four alleles, at fre-
quencies .40, .30, .20, and .10. For each family, 1,000
replicates were generated. Age at onset was defined ei-
ther as the age at which the individual reported aware-
ness of a significant change in gait pattern or as the age
at which a parent noted awkward gait or change in gait
in a child.
Mutation Detection
Each exon and flanking intronic sequence of the spas-
tin gene was amplified by PCR, from 100 ng of genomic
DNA extracted from peripheral blood samples from an
affected individual of each family. The sequences of the
primers and the conditions for PCR amplification have
been described elsewhere (by Genoscope Centre Na-
tional de Se´quenc¸age and Hazan et al. [1999], respec-
tively). The PCR products were run on 1% Agarose II
(Amresco), run on 0.5% Tris-borate EDTA (TBE) gels,
eluted from the gel by freezing and then centrifuging at
18,000 g for 10 min, and sequenced with the Thermo
Sequenase Radiolabeled Terminator Cycle Sequencing
Kit (USB). Potential mutations were tested for cosegre-
gation with the disease phenotype and were screened for
in 100 population-control individuals, by either re-
striction enzyme digestion or conformation sensitive gel
electrophoresis (Ko¨rkko¨ et al. 1998).
mRNA Expression Studies
Total RNA was extracted from patient lymphoblas-
toid cell lines or patient peripheral blood samples (as
available) or from normal human brain and was used
as a template for cDNA synthesis with random hexamer
and oligo dT15 primers and 200 U of Moloney murine
leukemia virus (M-MLV) reverse transcriptase (Life
Technologies), according to standard procedures. PCR
products amplified from the cDNA samples were run on
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Figure 1 Schematic of spastin cDNA. The thicker horizontal black line indicates the AAA cassette–encoding region of the gene; the thinner,
dashed lines indicate the leucine-zipper motif. The vertical lines indicate positions of mutations. Exons that are deleted as a result of splice-site
mutations are shaded. W p Walker motif; D p dimerization domain.
1% Agarose II, run on 0.5% TBE gels, and sequenced
as described above.
Subcloning and Transfection Experiments
PCR products spanning exon 5, exon 9, exons 10–12,
and exons 8–12, each with100 bp of flanking intronic
sequence, were amplified from patient genomic DNA.
The primers used were SPAex5a, SPAex5m, SPGex8a,
SPAex9a, SPAex9m, SPAex10a, and SPAex12m (Gen-
oscope Centre National de Se´quenc¸age), each with an
EcoRI or a BamHI restriction enzyme cleavage site–
compatible tail. These PCR products were cloned into
pSPL3 (Exon Trapping System; Life Technologies) and
then sequenced. Clones with or without the mutation of
interest, as well as the vector alone, were transfected
into COS1 cells, by use of Lipofectamine (Life Tech-
nologies), according to the manufacturer’s instructions.
Cytoplasmic RNAwas isolated from the transfected cells
after 36 h and then used as a template for cDNA syn-
thesis, with vector-specific primer SA2 (ATCTCAGTG-
GTATTTGTGAGC; Exon Trapping System) and 200 U
of M-MLV reverse transcriptase, according to the man-
ufacturer’s instructions. PCR products amplified from
the cDNA samples with vector-specific primers SD6
(TCTGAGTCACCTGGACAACC) and SA2 or exon-
specific primers, were run on 1% Agarose II, run on
0.5% TBE gels, and sequenced as described above.
Results
Mutation Detection
In 11 of the 15 families screened (table 1), we iden-
tified spastin gene mutations, 10 of which were novel.
One missense mutation, 1620CrT (R499C), has been
described elsewhere (Hazan et al. 1999), and it should
be noted that this CrT transition occurs at a CpG di-
nucleotide. Figure 1 shows a schematic of the spastin
cDNA and the positions of the mutations identified in
this study. In addition to one nonsense mutation, one
frameshift mutation, and two missense-only mutations,
we identified seven mutations that affect splicing, one of
which is also a missense mutation (995GrT [K290N];
fig. 2). We found no obvious relationship between the
type or location of the mutations and the age at onset
of symptoms (table 1). The age at onset varied widely,
both within and among the families, and the average
age at onset did not differ markedly among the families.
The nonsense mutation that we identified, 465GrT,
causes a change from a glutamic acid to a stop codon
in exon 1. The frameshift mutation that we identified,
1486insA, occurs in exon 11, in the AAA cassette–
encoding region of the gene. We identified threemissense
mutations, one of which also affects splicing. The
1620CrT and 1809CrG mutations both result in a
nonconservative amino acid codon change—from, re-
spectively, an arginine to a cysteine codon (R499C) in
exon 13 and from an arginine to a glycine codon
(R562G) in exon 15. Both of these arginine residues are
located in the AAA cassette, and both are conserved
among spastin homologs in yeast, Caenorhabditis ele-
gans, and mice (Hazan et al. 1999). The third missense
mutation, 995GrT (K290N), also results in a noncon-
servative amino acid codon change, from a lysine to an
asparagine codon at the 3′ end of exon 5. This mutation
also disrupts splicing: it causes skipping of exon 5, with
a consequent frameshift, as demonstrated by reverse
transcription–PCR (RT-PCR) analysis (fig. 2).
We identified seven mutations that affect splicing. Each
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Figure 2 Aberrant splicing resulting from the 995GrT mutation. A, Schematic showing the position of the G995T mutation in family
1713 (top) and RT-PCR products from lymphocyte RNA from two affected individuals from family 1713 (bottom). For this and subsequent
figures, the identity of each RT-PCR–product band was confirmed by DNA sequencing. The mutation causes skipping of exon 5. A normal
splice variant missing exon 4 is found in samples from both control subjects and affected individuals. B, RT-PCR products showing the presence
of the normal splice variant lacking exon 4, in RNA extracted from a sample of normal human brain tissue.
mutation either lies within the AAA cassette–encoding
region of the gene or affects splicing of an exon in this
region. Only two of the mutations are located in an in-
variant (GT–––AG) donor or acceptor splice-site se-
quence. The splice-acceptor–site mutation IVS122ArC
causes skipping of exon 13 (fig. 3), and the splice-do-
nor–site mutation IVS91GrA causes skipping of exon
9 (fig. 4). Both of these exons lie within the AAA cas-
sette–encoding region of the gene.
The remaining five mutations that affect splicing are
located outside the invariant (GT–––AG) splice-site
sequences. Four of them—995GrT, IVS94ArG,
IVS96TrG, and IVS112insT—result in skipping of
an entire exon (figs. 2, 4, and 5). The fifth mutation,
1367ArG, results in the creation of a new splice-donor
site 4 nt upstream of the 3′ end of exon 9, causing
deletion of the last 4 nt of exon 9 (fig. 6).
We also detected one synonymous substitution,
1004GrA (P293P), in exon 6 in the proband of family
1838. This nucleotide change was found in a single in-
dividual in the youngest generation of the pedigree and
was not found in 84 control individuals. To our knowl-
edge, no other polymorphisms have been detected in a
spastin gene coding exon.
mRNA Expression Studies
During the RT-PCR analysis of RNA isolated from
lymphocytes, we identified three spastin mRNA splice
variants, in both control and patient samples; we also
identified these same variants in RNA extracted from a
sample of normal human brain. In all cases, the splice
variant, as visualized by gel electrophoresis, was less
abundant than the full-length spastin transcript. Figure
2 shows skipping of exon 4 in both control and patient
samples; this skipped exon is upstream of the AAA-cas-
sette region, and the transcript retains the correct reading
frame. Another normal splice variant lacks exon 8,
which lies within the AAA-cassette region and includes
the Walker A motif; this transcript also retains the cor-
rect reading frame. The third normal splice variant is
missing exon 15, which also lies within the AAA-cassette
region but downstream of the Walker A and B motifs,
the helix-loop-helix dimerization domain, and the leu-
cine-zipper motif. However, unlike skipping of exon 4
or exon 5, skipping of exon 15 causes a frameshift. All
three of these splice variants were detected consistently,
although, particularly in the case of the last two, at very
low levels. After accounting for these normal splice var-
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Figure 3 Aberrant splicing resulting from the IVS122ArCmu-
tation. Top, Schematic showing the position of the IVS122ArCmu-
tation in family 1858. Bottom, RT-PCR products from lymphocyte
RNA from two affected individuals from family 1858. The mutation
causes skipping of exon 13.
Figure 4 Aberrant splicing resulting from the IVS112T inser-
tion and the IVS91GrA mutation. Top, Schematic showing the po-
sitions of the IVS112T insertion in family 2187 and of the
IVS91GrA mutation in family 1974. Bottom, RT-PCR products
from lymphocyte RNA from three affected individuals, one from fam-
ily 2187 and two from family 1974. The mutation in family 2187
causes skipping of exon 11, and the mutation in family 1974 causes
skipping of exon 9.
iants, we could easily interpret the results of our mRNA
expression studies.
In four of the six splice-site–mutation cases for which
patient-derived RNA was available for study, the aber-
rant-size transcript, as visualized by gel electrophoresis,
was much less abundant than the wild-type transcript.
This may indicate that the mutant transcript is either
less stable or expressed at a lower level than is the wild-
type transcript. Alternatively, these mutations may be
“leaky,” or not fully penetrant; that is, some normally
spliced transcript may be produced from the mutant al-
lele. In two cases, sequence variation within the tran-
script allowed us to test the latter possibility. In the case
of the 995GrT mutation in exon 5, which also causes
aberrant splicing (fig. 2), homozygosity was detected at
position 995 (the site of the mutation) in the normally
spliced transcript, indicating that normally spliced tran-
script was produced exclusively from the wild-type al-
lele. In contrast, both aberrantly and normally spliced
transcripts were produced from the allele with the
IVS94ArG mutation (fig. 5A). To exclude any am-
plification of aberrantly spliced transcripts, we designed
one of the amplification primers in exon 9, which is
absent from the aberrantly spliced transcript. Subse-
quent sequencing of the full-length transcript, with either
primer used in the amplification, revealed heterozygosity
for the 1004GrA private polymorphism in exon 6 (fig.
5B). This indicates that the full-length, normally spliced
transcript was produced from both the wild-type and
the mutant allele in this patient.
Unfortunately, for the other splice-site mutations that
we identified, no coding-region polymorphismwas avail-
able to determine whether a given transcript was pro-
duced from the mutant or the wild-type allele. To de-
termine whether any of the other splice-site mutations
were leaky, we expressed them separately, in vitro, to
examine their effect on splicing independent of the wild-
type allele. We subcloned the mutations, with surround-
ing genomic sequence into an exon-trapping vector,
pSPL3, and transfected these minigene constructs into
COS1 cells, for mRNA expression studies. As shown in
figure 7, none of the mutations—including the
IVS94ArG mutation that we had found to be leaky
in vivo—caused aberrant splicing in this in vitro system.
However, in all but one of these cases, the construct
contained only the exon affected by the mutation, along
with flanking intronic sequence. To determine whether
the leakiness of the IVS94ArG mutation would be
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Figure 5 Aberrant splicing resulting from the leaky IVS94ArG mutation. A, Schematic showing the position of the IVS94ArG
mutation in family 1838 (top) and RT-PCR products from lymphocyte RNA from an affected individual from family 1838 (bottom). The
mutation causes skipping of exon 9. A normal splice variant missing exon 8 is reproducibly found in samples both from control subjects and
from affected individuals. In this figure, it is barely visible in the control lane. In the lane for family 1838, the middle band represents both the
mutant transcript missing exon 9 and the normal splice variant missing exon 8 and thus is more easily visible. B, Sequencing-gel autoradiograph
showing heterozygosity for the 1004GrA private polymorphism in exon 6 in normally spliced transcript. RNA from lymphocytes from an
affected individual from family 1838 was analyzed by RT-PCR. To prevent amplification of any contaminating mutant transcript, a reverse
primer was chosen in exon 9, which is absent from the mutant transcript (for positions of primers, see A). The sequence of the normally spliced
full-length transcript is heterozygous for the 1004GrA private polymorphism in exon 6 (arrow). This heterozygosity was present both in the
sequence generated with the exon 5–specific primer (shown) and in sequence generated with the exon 9–specific primer.
reproduced in a more extensive genomic-sequence con-
text in vitro, we used a minigene construct containing
additional flanking exons and intronic sequence (fig. 8).
In this sequence context, both full-length and mutant
(missing exon 9) transcripts were produced from the
mutant construct.
Discussion
Each of the four families in whom we found no spastin
gene mutations was relatively small, with the maximum
LOD score !1.5 for SPG4-linked markers. Although it
is possible that these families harbor an undetected mu-
tation either in the spastin gene or in one of its regulatory
regions, it is also possible that they instead segregate a
mutation either at one of the six other autosomal domi-
nant SPG loci that have been identified to date or at an
unidentified SPG locus (Fontaine et al. 2000; Mc-
Dermott et al. 2000; Reid et al. 2000). A genomewide
screen of these families for evidence of linkage to other
loci is currently under way.
All of the mutations identified in this study are con-
sistent with loss of spastin function, consistent with the
previously described mutations. The importance of the
AAA cassette in spastin function is suggested by its high
degree of conservation among AAA protein family
members and by the locations of the spastin gene mu-
tations identified to date. The AAA cassette contains
Walker A and Bmotifs (the putative sites of ATP binding
and ATPase activity), a helix-loop-helix dimerization
domain, and a leucine-zipper motif. All of the mutations
identified in the present study are predicted to affect the
AAA cassette, with all but one affecting one or more
of the known motifs in this region; the lone exception,
the 1809CrG mutation in exon 15, alters a highly con-
served arginine residue within the AAA cassette. The
region outside the AAA cassette is much less conserved
among members of the very large family of AAA pro-
teins (Patel and Latterich 1998). Nonetheless, at the
amino acid level, human spastin is 96% identical to its
mouse ortholog, throughout the protein. This high level
of identity and the extremely low level of polymorphism
throughout the coding exons of the spastin gene suggest
a low level of tolerance for amino acid substitutions,
throughout the protein. This is in contrast to the tol-
erance, at least to some extent, for variability at the
level of spastin mRNA splicing. Two of the normal
splice variants that we identified directly affect the AAA-
cassette region of the protein. The functional signifi-
cance of these splice variants is unclear, but their pres-
ence may suggest functions for spastin that are
independent of the AAA cassette.
The majority of mutations that we identified create
aberrant splice variants of the spastin transcript. Al-
though our findings regarding the effects of the splice-
site mutations were in lymphocytes, each of these mu-
tations causes skipping of an exon that is otherwise
included in all splice variants identified to date, includ-
ing transcripts derived from brain RNA. Since these
exons do not appear to be affected by alternative splic-
ing, they should be processed by the splicing machinery
common to all cell types. As such, these mutations
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Figure 6 Aberrant splicing resulting from the 1367ArG mu-
tation. Top, Schematic showing the position of the 1367ArGmutation
in family 1676. Bottom, Sequencing-gel autoradiograph showing de-
letion of 4 nt at the 3′ end of exon 9 in the mutant transcript. Total
RT-PCR product (heterozygote) or electrophoretically separated prod-
ucts (mutant and wild-type transcripts) are shown.
Figure 7 Effects of splice-site mutations on mRNA splicing in
COS1 cells. The pSPL3 exon-trapping vector was used to assay splice-
site selection. A, Cells were transfected with vector alone (lane pSPL3),
or with wild-type exon 9 and flanking intronic sequence (lane ex 9
wt), or with the same construct but containing the mutations identified
in the four families indicated (lanes 1676, 1838, 1974, and 2082). RT-
PCR products were amplified with vector-specific primers. The mu-
tations in families 1838, 1974, and 2082 cause skipping of exon 9;
the mutation in family 1676 causes a 4-nt deletion from exon 9 (see
fig. 6). B, Cells were transfected with vector alone (lane pSPL3), or
with wild-type exon 5 and flanking intronic sequence (lane ex 5 wt),
or with the same construct but containing the mutation identified in
family 1713 (lane 1713). RT-PCR products were amplifiedwith vector-
specific primers. The mutation causes skipping of exon 5. C, Cells
were transfected with vector alone (lane pSPL3), or with wild-type
exons 10–12 and flanking intronic sequence (lane ex 10-12-wt), or
with the same construct but containing the mutation identified in fam-
ily 2187 (lane 2187). RT-PCR products were amplified with vector-
specific primers. The mutation causes skipping of exon 11.
should have the same effects that we observed in neu-
rons and other types of cells.
Both normal and mutant (deletion of exon 9) tran-
scripts were produced from the IVS94ArG mutant
allele in the RT-PCR analysis of patient-derived RNA.
This led us to investigate whether some of the other
mutations were also leaky. In analysis with an in vitro
exon-trapping construct, none of the mutations ap-
peared to be leaky, even IVS94ArG, which appeared
to be leaky in vivo. Although this may be explained by
differences between the cell types used in these distinct
approaches, we surmised that it was instead due to dif-
ferences in genomic sequence context—in particular, the
strengths of the donor and acceptor splice-site sequences
of adjacent exons. When we included additional ge-
nomic sequence including the endogenous splice junc-
tions flanking the skipped exon, the leakiness of the
IVS94ArGmutation was restored. We note that exon
trapping and other minigene constructs commonly used
in this type of analysis contain strong, viral-based donor
and acceptor splice-site sequences within the vector,
chosen for maximum splicing efficiency. These se-
quences could alter the effects of sequence variation that
might affect splice-site selection. Thus, mutations that
may be leaky in vivo may appear to be fully penetrant
in the absence of extensive genomic-sequence context
of the gene being investigated. Our findings suggest cau-
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Figure 8 Differences in splice-site selection due to the IVS94ArG mutation depend on the extent of flanking genomic sequence context.
The pSPL3 exon-trapping vector was used to assay splice-site selection. A, Cells were transfected with vector alone (lane pSPL3), or with wild-
type exons 8–12 and flanking intronic sequence (lane ex 10-12-wt), or with the same construct but containing the mutation identified in family
1838 (lane 1838). RT-PCR products were amplified with vector-specific primers. In this minimal genomic sequence context, all transcripts
produced from the mutant allele lack exon 9. B, Cells were transfected with wild-type exons 8–12 and flanking intronic sequence (lane ex 8-
12 wt), or with the same transcript but containing the mutation identified in family 1838 (lane 1838). RT-PCR products were amplified with
primers specific to exons 8 (forward primer) and 11 (reverse primer). In this more extensive genomic sequence context, the mutation is leaky.
Both the full-length transcript and the transcript lacking exon 9 are produced from the mutant allele. The structures of the constructs used are
shown at the top of each panel.
tion in the interpretation of data solely obtained with
minigene constructs to study the effects of sequence var-
iation on splicing.
The variable expressivity of SPG—and, in particular,
that linked to SPG4—has been widely noted, to the
extent that some earlier literature suggested anticipation
for SPG4-linked families (Scott et al. 1997; McDermott
et al. 2000). These suggestions have abated since the
identification of inactivating spastin gene mutations,
rather than a trinucleotide-repeat expansion; however,
for the wide variability in phenotype, an account must
still be made. If a model of haploinsufficiency for SPG4-
linked SPG is assumed, the progression from normal
function to disease state would appear to require a 50%
reduction in spastin level. Our data, showing the pro-
duction of normally spliced transcripts from at least one
mutant spastin allele, suggest that the threshold of spas-
tin required for this progression lies within a much nar-
rower interval. Thus, relatively small differences in the
level of wild-type spastin expression may have impor-
tant functional consequences. Although the normal
range of variability in spastin-expression level is un-
known, in the context of a spastin-gene mutation—even
a fully penetrant (i.e., nonleaky) mutation—such vari-
ability might be brought into a range in which it has
dramatic phenotypic consequences. If the function of
spastin is highly concentration dependent, consistent
with the IVS94ArG mutation, the phenotype could
vary in parallel with spastin levels. This may, at least
in part, account for the wide ranges in age at onset,
symptom severity, and rate of symptom progression that
have been reported to occur in SPG4-linked SPG, both
among and within families.
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